GSK (GSK) vs BeOne Medicines (ONC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GSK (GSK) has outperformed BeOne Medicines (ONC) over the past year, gaining 7.4% versus a loss of 0.3%. Over five years, GSK leads with a +19.3% price change compared with -2.3% for ONC. GSK is the larger company by market cap ($93.16 billion vs $40.33 billion), about 2.3 times the size.
On valuation, GSK trades at a lower forward P/E (9.4x vs 34.6x for BeOne Medicines). GSK pays a dividend yielding 1.46%, while BeOne Medicines does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GSK | ONC |
|---|---|---|
| Share price | $46.50 | $354.47 |
| Market cap | $93.16B | $40.33B |
| 1-day change | -0.09% | +1.24% |
| YTD return | -5.10% | +15.25% |
| 1-year return | +7.36% | -0.27% |
| 5-year return | +19.30% | -2.32% |
| P/E ratio (TTM) | 14.67 | 63.41 |
| Forward P/E | 9.41 | 34.58 |
| EPS (TTM) | $3.17 | $5.59 |
| Dividend yield | 1.46% | 0.00% |
| Annual dividend | $0.68 | $0.00 |
| Revenue (latest FY) | — | $5.34B |
| Revenue growth (YoY) | — | +40.23% |
| Net income (latest FY) | — | $286.93M |
| Gross margin | — | 87.49% |
| Operating margin | — | 8.37% |
| Net margin | — | 5.37% |
| 52-week high | $61.70 | $385.22 |
| 52-week low | $42.85 | $253.95 |
| Distance from 52-week high | -24.64% | -7.98% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +27.59% | +22.77% |
| Average volume | 3.85M | 393.32K |
| Shares outstanding | 2.00B | 104.92M |
| Employees | 66,841 | 12,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GSK is about 2.3 times larger than BeOne Medicines by market value ($93.16B vs $40.33B).
- BeOne Medicines trades at a higher earnings multiple (63.4x vs 14.7x trailing P/E).
- GSK offers a meaningfully higher dividend yield (1.46% vs 0.00%).
About GSK
GSK stock →GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 66,841 employees
About BeOne Medicines
ONC stock →BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 12,000 employees
GSK vs ONC FAQ
Which is bigger, GSK or BeOne Medicines?
GSK (GSK) is larger, with a market capitalization of $93.16B compared with $40.33B for BeOne Medicines (ONC).
Which stock has performed better over the past year, GSK or ONC?
GSK returned +7.36% over the past 12 months, compared with -0.27% for ONC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, GSK or ONC?
GSK has the lower trailing P/E at 14.7, versus 63.4 for ONC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, GSK or BeOne Medicines?
GSK pays a dividend yielding 1.46%, while BeOne Medicines does not currently pay a regular dividend.
Are GSK and BeOne Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.